MedTrace Logo

Treatment of Malignant Melanoma With GPA-TriMAR-T Cell Therapy

NCT03649529 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2019-12-06

No results posted yet for this study

Summary

Malignant melanoma have been reported to be characterized with high gp100 expression. Patients' autologous T cells will be isolated and transduced by GPA-TriMAR lentivirus to generate the GPA-TriMAR-T cells. When infused back to the patient, the GPA-TriMAR-T cells will recognize and kill target cells that express gp100(209-217) peptides in the form MHC-I complex, thus eliminating malignant melanoma from the body.

Conditions

  • Malignant Melanoma

Interventions

BIOLOGICAL

GPA-TriMAR-T

Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.

Sponsors & Collaborators

  • The Second Affiliated Hospital of Hainan Medical University

    collaborator OTHER

  • Hainan Cancer Hospital

    collaborator OTHER

  • Timmune Biotech Inc.

    lead INDUSTRY

Principal Investigators

  • Haifeng Lin · The Second Affiliated Hospital of Hainan Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
69 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-27
Primary Completion
2021-09-15
Completion
2022-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03649529 on ClinicalTrials.gov